Progentec Diagnostics has entered into a strategic collaboration with Mayo Clinic Laboratories to commercialise its biomarker blood tests for the management of autoimmune diseases.

The collaboration aims to increase the accessibility of Progentec’s biomarker blood tests for providers and patients across the US and other global markets.

As part of the partnership, Mayo Clinic Laboratories chief administrative officer Mary Jo Williamson has been appointed to the Progentec board of directors.

Williamson oversees the Mayo Clinic diagnostic business lines, including Mayo Clinic Laboratories and Remote Diagnostics.

Mayo Clinic said that it has a financial interest in the Progentec technology and will use any revenue generated from the partnership to support its not-for-profit mission.

Mayo Clinic Laboratories CEO William Morice II said: “Progentec’s understanding of the immunologic foundations, combined with Mayo Clinic Laboratories’ expertise as a world leader in lab services, provides hope for a significant unmet need for patients.

“Additionally, the collaboration will facilitate Mayo Clinic experts to provide guidance on ways to enhance test adoption and promote appropriate use.”

Progentec Diagnostics CEO Mohan Purushothaman said: “The work represents a significant step forward in our mission to provide robust testing services that contribute to the health and well-being of individuals and communities with autoimmune conditions.”

Progentec Diagnostics is a digital health and diagnostic company focused on improving outcomes in patients with autoimmune diseases.

Earlier this year, the diagnostic company initiated PROACTIVE, a collaborative study with GSK to identify individuals at risk of lupus and guide them through a virtual diagnostic journey.

Lupus is a chronic autoimmune disease that can be effectively treated and managed through early detection and diagnosis.

The PROACTIVE study aims to help individuals take control of their health by providing them with a completely personalised approach to evaluate their symptoms.

The study will guide individuals at risk of developing lupus through a virtual diagnostic journey that includes online assessments, biomarker tests, and virtual consultations with specialists.